Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$129 Mln
P/E Ratio
--
P/B Ratio
9.7
Industry P/E
--
Debt to Equity
3.96
ROE
-3.37 %
ROCE
-118.67 %
Div. Yield
0 %
Book Value
0.3
EPS
-1.89
CFO
$-255.70 Mln
EBITDA
$-254.25 Mln
Net Profit
$-279.78 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Scpharmaceuticals Inc (SCPH)
| -26.55 | -13.33 | -19.00 | -43.11 | -19.96 | -22.83 | -- |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Scpharmaceuticals Inc (SCPH)
| -43.28 | -12.55 | 42.83 | -5.10 | -6.54 | 50.53 | -68.70 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 61.94 | 11,346.08 | 26.54 | 8.05 | |
| 69.27 | 6,636.14 | 51.14 | 23.56 | |
| 58.00 | 11,265.03 | 378.67 | 0.76 | |
| 7.82 | 9,036.23 | -- | -3.24 |
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered... through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. Its product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. The company has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts. Address: 25 Mall Road, Burlington, MA, United States, 01803 Read more
President, CEO, Principal Executive Officer & Director
Mr. John H. Tucker
President, CEO, Principal Executive Officer & Director
Mr. John H. Tucker
Headquarters
Burlington, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Scpharmaceuticals Inc (SCPH) stood at $ 108 Mln as on 31-Dec-24
The share price of Scpharmaceuticals Inc (SCPH) is $2.60 (NASDAQ) as of 23-Apr-2025 16:01 EDT. Scpharmaceuticals Inc (SCPH) has given a return of -19.96% in the last 3 years.
Scpharmaceuticals Inc (SCPH) has a market capitalisation of $ 129 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Scpharmaceuticals Inc (SCPH) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Scpharmaceuticals Inc (SCPH) and enter the required number of quantities and click on buy to purchase the shares of Scpharmaceuticals Inc (SCPH).
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. Its product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. The company has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts. Address: 25 Mall Road, Burlington, MA, United States, 01803
The CEO & director of Mr. John H. Tucker. is Scpharmaceuticals Inc (SCPH), and CFO & Sr. VP is Mr. John H. Tucker.
There is no promoter pledging in Scpharmaceuticals Inc (SCPH).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,131
|
|
|
1,128
|
|
|
882
|
|
|
682
|
| Scpharmaceuticals Inc (SCPH) | Ratios |
|---|---|
|
Return on equity(%)
|
-336.97
|
|
Operating margin(%)
|
-213.53
|
|
Net Margin(%)
|
-234.36
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Scpharmaceuticals Inc (SCPH) was $0 Mln.
$-0.01
(
